nodes	percent_of_prediction	percent_of_DWPC	metapath
Aripiprazole—ABCB1—peripheral nervous system neoplasm	0.199	1	CbGaD
Aripiprazole—CYP3A7-CYP3A51P—Tretinoin—peripheral nervous system neoplasm	0.0417	0.132	CbGbCtD
Aripiprazole—CYP3A7—Tretinoin—peripheral nervous system neoplasm	0.0417	0.132	CbGbCtD
Aripiprazole—CYP3A5—Tretinoin—peripheral nervous system neoplasm	0.0313	0.0987	CbGbCtD
Aripiprazole—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0219	0.0691	CbGbCtD
Aripiprazole—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0219	0.0691	CbGbCtD
Aripiprazole—CYP3A7—Vincristine—peripheral nervous system neoplasm	0.0192	0.0604	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Vincristine—peripheral nervous system neoplasm	0.0192	0.0604	CbGbCtD
Aripiprazole—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.0152	0.0479	CbGbCtD
Aripiprazole—CYP3A5—Vincristine—peripheral nervous system neoplasm	0.0144	0.0453	CbGbCtD
Aripiprazole—CYP3A5—Etoposide—peripheral nervous system neoplasm	0.0132	0.0415	CbGbCtD
Aripiprazole—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0131	0.0414	CbGbCtD
Aripiprazole—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0122	0.0385	CbGbCtD
Aripiprazole—ABCB1—Vincristine—peripheral nervous system neoplasm	0.00935	0.0295	CbGbCtD
Aripiprazole—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.00872	0.0275	CbGbCtD
Aripiprazole—HTR1D—meninx—peripheral nervous system neoplasm	0.00868	0.0892	CbGeAlD
Aripiprazole—ABCB1—Etoposide—peripheral nervous system neoplasm	0.00857	0.027	CbGbCtD
Aripiprazole—HTR1B—dura mater—peripheral nervous system neoplasm	0.00825	0.0848	CbGeAlD
Aripiprazole—HTR1D—dura mater—peripheral nervous system neoplasm	0.00799	0.0821	CbGeAlD
Aripiprazole—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00584	0.0184	CbGbCtD
Aripiprazole—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.0056	0.0177	CbGbCtD
Aripiprazole—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00551	0.0174	CbGbCtD
Aripiprazole—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00513	0.0162	CbGbCtD
Aripiprazole—HTR2A—phrenic nerve—peripheral nervous system neoplasm	0.00467	0.0479	CbGeAlD
Aripiprazole—HTR3A—vagus nerve—peripheral nervous system neoplasm	0.00396	0.0406	CbGeAlD
Aripiprazole—HTR1B—trigeminal nerve—peripheral nervous system neoplasm	0.00355	0.0364	CbGeAlD
Aripiprazole—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.0035	0.011	CbGbCtD
Aripiprazole—HTR1D—trigeminal nerve—peripheral nervous system neoplasm	0.00343	0.0353	CbGeAlD
Aripiprazole—HTR3A—cranial nerve—peripheral nervous system neoplasm	0.00301	0.0309	CbGeAlD
Aripiprazole—HTR7—vagus nerve—peripheral nervous system neoplasm	0.00256	0.0263	CbGeAlD
Aripiprazole—HTR1B—cranial nerve—peripheral nervous system neoplasm	0.00253	0.026	CbGeAlD
Aripiprazole—HTR1D—cranial nerve—peripheral nervous system neoplasm	0.00245	0.0251	CbGeAlD
Aripiprazole—HTR6—ganglion—peripheral nervous system neoplasm	0.00212	0.0218	CbGeAlD
Aripiprazole—DRD5—ganglion—peripheral nervous system neoplasm	0.00207	0.0212	CbGeAlD
Aripiprazole—HTR7—cranial nerve—peripheral nervous system neoplasm	0.00195	0.02	CbGeAlD
Aripiprazole—HTR7—pons—peripheral nervous system neoplasm	0.00193	0.0198	CbGeAlD
Aripiprazole—HTR2A—trigeminal nerve—peripheral nervous system neoplasm	0.00171	0.0175	CbGeAlD
Aripiprazole—DRD1—nerve—peripheral nervous system neoplasm	0.0016	0.0164	CbGeAlD
Aripiprazole—HTR2A—vagus nerve—peripheral nervous system neoplasm	0.0016	0.0164	CbGeAlD
Aripiprazole—DRD1—ganglion—peripheral nervous system neoplasm	0.00158	0.0162	CbGeAlD
Aripiprazole—HTR3A—nerve—peripheral nervous system neoplasm	0.00154	0.0159	CbGeAlD
Aripiprazole—HTR3A—ganglion—peripheral nervous system neoplasm	0.00153	0.0157	CbGeAlD
Aripiprazole—HTR1B—ganglion—peripheral nervous system neoplasm	0.00128	0.0131	CbGeAlD
Aripiprazole—HTR1D—ganglion—peripheral nervous system neoplasm	0.00124	0.0127	CbGeAlD
Aripiprazole—HTR2C—ganglion—peripheral nervous system neoplasm	0.00123	0.0126	CbGeAlD
Aripiprazole—HTR2A—cranial nerve—peripheral nervous system neoplasm	0.00122	0.0125	CbGeAlD
Aripiprazole—HTR2A—pons—peripheral nervous system neoplasm	0.0012	0.0123	CbGeAlD
Aripiprazole—HTR1E—brainstem—peripheral nervous system neoplasm	0.00118	0.0121	CbGeAlD
Aripiprazole—SLC6A4—ganglion—peripheral nervous system neoplasm	0.00116	0.0119	CbGeAlD
Aripiprazole—HTR1A—ganglion—peripheral nervous system neoplasm	0.00103	0.0106	CbGeAlD
Aripiprazole—HTR7—nerve—peripheral nervous system neoplasm	0.000999	0.0103	CbGeAlD
Aripiprazole—HTR7—ganglion—peripheral nervous system neoplasm	0.000987	0.0101	CbGeAlD
Aripiprazole—DRD2—nerve—peripheral nervous system neoplasm	0.000945	0.0097	CbGeAlD
Aripiprazole—DRD2—ganglion—peripheral nervous system neoplasm	0.000933	0.00958	CbGeAlD
Aripiprazole—H1F0—trigeminal ganglion—peripheral nervous system neoplasm	0.000785	0.00807	CbGeAlD
Aripiprazole—HTR3A—trigeminal ganglion—peripheral nervous system neoplasm	0.000749	0.00769	CbGeAlD
Aripiprazole—H1F0—parotid gland—peripheral nervous system neoplasm	0.000741	0.00761	CbGeAlD
Aripiprazole—DRD1—brainstem—peripheral nervous system neoplasm	0.000686	0.00705	CbGeAlD
Aripiprazole—HTR3A—brainstem—peripheral nervous system neoplasm	0.000663	0.00681	CbGeAlD
Aripiprazole—HTR1B—trigeminal ganglion—peripheral nervous system neoplasm	0.000628	0.00645	CbGeAlD
Aripiprazole—HTR2A—nerve—peripheral nervous system neoplasm	0.000623	0.0064	CbGeAlD
Aripiprazole—HTR2A—ganglion—peripheral nervous system neoplasm	0.000615	0.00632	CbGeAlD
Aripiprazole—HTR1D—trigeminal ganglion—peripheral nervous system neoplasm	0.000608	0.00625	CbGeAlD
Aripiprazole—HTR1B—brainstem—peripheral nervous system neoplasm	0.000556	0.00571	CbGeAlD
Aripiprazole—HTR1D—brainstem—peripheral nervous system neoplasm	0.000538	0.00553	CbGeAlD
Aripiprazole—CHRM1—parotid gland—peripheral nervous system neoplasm	0.000537	0.00551	CbGeAlD
Aripiprazole—HTR2C—brainstem—peripheral nervous system neoplasm	0.000533	0.00548	CbGeAlD
Aripiprazole—SLC6A4—brainstem—peripheral nervous system neoplasm	0.000505	0.00519	CbGeAlD
Aripiprazole—KCNH2—trigeminal ganglion—peripheral nervous system neoplasm	0.000452	0.00464	CbGeAlD
Aripiprazole—HTR1A—brainstem—peripheral nervous system neoplasm	0.000449	0.00461	CbGeAlD
Aripiprazole—ADRA2C—trigeminal ganglion—peripheral nervous system neoplasm	0.000445	0.00458	CbGeAlD
Aripiprazole—HTR7—brainstem—peripheral nervous system neoplasm	0.000429	0.00441	CbGeAlD
Aripiprazole—ADRA2C—parotid gland—peripheral nervous system neoplasm	0.00042	0.00432	CbGeAlD
Aripiprazole—ADRA1A—brainstem—peripheral nervous system neoplasm	0.000414	0.00425	CbGeAlD
Aripiprazole—DRD2—brainstem—peripheral nervous system neoplasm	0.000406	0.00417	CbGeAlD
Aripiprazole—HRH1—trigeminal ganglion—peripheral nervous system neoplasm	0.000362	0.00372	CbGeAlD
Aripiprazole—ADRA2A—trigeminal ganglion—peripheral nervous system neoplasm	0.000355	0.00365	CbGeAlD
Aripiprazole—H1F0—cerebellum—peripheral nervous system neoplasm	0.000343	0.00352	CbGeAlD
Aripiprazole—HTR2A—brainstem—peripheral nervous system neoplasm	0.000267	0.00275	CbGeAlD
Aripiprazole—CYP2D6—brainstem—peripheral nervous system neoplasm	0.000244	0.0025	CbGeAlD
Aripiprazole—HTR1A—cerebellum—peripheral nervous system neoplasm	0.000221	0.00227	CbGeAlD
Aripiprazole—HTR7—cerebellum—peripheral nervous system neoplasm	0.000211	0.00217	CbGeAlD
Aripiprazole—ADRA1A—cerebellum—peripheral nervous system neoplasm	0.000204	0.00209	CbGeAlD
Aripiprazole—DRD2—cerebellum—peripheral nervous system neoplasm	0.0002	0.00205	CbGeAlD
Aripiprazole—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	0.000198	0.00203	CbGeAlD
Aripiprazole—KCNH2—cerebellum—peripheral nervous system neoplasm	0.000197	0.00202	CbGeAlD
Aripiprazole—ADRA2C—cerebellum—peripheral nervous system neoplasm	0.000194	0.002	CbGeAlD
Aripiprazole—ADRA2A—cerebellum—peripheral nervous system neoplasm	0.000155	0.00159	CbGeAlD
Aripiprazole—HTR2A—cerebellum—peripheral nervous system neoplasm	0.000132	0.00135	CbGeAlD
Aripiprazole—CYP2D6—cerebellum—peripheral nervous system neoplasm	0.00012	0.00123	CbGeAlD
Aripiprazole—ABCB1—cerebellum—peripheral nervous system neoplasm	8.64e-05	0.000888	CbGeAlD
Aripiprazole—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	4.71e-05	0.000151	CcSEcCtD
Aripiprazole—Fatigue—Etoposide—peripheral nervous system neoplasm	4.71e-05	0.000151	CcSEcCtD
Aripiprazole—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	4.71e-05	0.000151	CcSEcCtD
Aripiprazole—Stomatitis—Epirubicin—peripheral nervous system neoplasm	4.68e-05	0.00015	CcSEcCtD
Aripiprazole—Jaundice—Epirubicin—peripheral nervous system neoplasm	4.68e-05	0.00015	CcSEcCtD
Aripiprazole—Pain—Etoposide—peripheral nervous system neoplasm	4.67e-05	0.00015	CcSEcCtD
Aripiprazole—Constipation—Etoposide—peripheral nervous system neoplasm	4.67e-05	0.00015	CcSEcCtD
Aripiprazole—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	4.67e-05	0.000149	CcSEcCtD
Aripiprazole—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	4.67e-05	0.000149	CcSEcCtD
Aripiprazole—Dysuria—Doxorubicin—peripheral nervous system neoplasm	4.66e-05	0.000149	CcSEcCtD
Aripiprazole—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	4.66e-05	0.000149	CcSEcCtD
Aripiprazole—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	4.63e-05	0.000148	CcSEcCtD
Aripiprazole—Dizziness—Alitretinoin—peripheral nervous system neoplasm	4.63e-05	0.000148	CcSEcCtD
Aripiprazole—Diarrhoea—Vincristine—peripheral nervous system neoplasm	4.61e-05	0.000148	CcSEcCtD
Aripiprazole—Sweating—Epirubicin—peripheral nervous system neoplasm	4.6e-05	0.000147	CcSEcCtD
Aripiprazole—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	4.6e-05	0.000147	CcSEcCtD
Aripiprazole—Haematuria—Epirubicin—peripheral nervous system neoplasm	4.58e-05	0.000147	CcSEcCtD
Aripiprazole—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	4.55e-05	0.000146	CcSEcCtD
Aripiprazole—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	4.54e-05	0.000145	CcSEcCtD
Aripiprazole—Weight increased—Doxorubicin—peripheral nervous system neoplasm	4.53e-05	0.000145	CcSEcCtD
Aripiprazole—Epistaxis—Epirubicin—peripheral nervous system neoplasm	4.53e-05	0.000145	CcSEcCtD
Aripiprazole—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	4.51e-05	0.000144	CcSEcCtD
Aripiprazole—Sinusitis—Epirubicin—peripheral nervous system neoplasm	4.5e-05	0.000144	CcSEcCtD
Aripiprazole—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	4.5e-05	0.000144	CcSEcCtD
Aripiprazole—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	4.49e-05	0.000144	CcSEcCtD
Aripiprazole—Nausea—Dactinomycin—peripheral nervous system neoplasm	4.48e-05	0.000143	CcSEcCtD
Aripiprazole—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	4.48e-05	0.000143	CcSEcCtD
Aripiprazole—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	4.47e-05	0.000143	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	4.47e-05	0.000143	CcSEcCtD
Aripiprazole—Dizziness—Vincristine—peripheral nervous system neoplasm	4.46e-05	0.000143	CcSEcCtD
Aripiprazole—Vomiting—Alitretinoin—peripheral nervous system neoplasm	4.45e-05	0.000142	CcSEcCtD
Aripiprazole—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	4.44e-05	0.000142	CcSEcCtD
Aripiprazole—Infestation—Doxorubicin—peripheral nervous system neoplasm	4.44e-05	0.000142	CcSEcCtD
Aripiprazole—Rash—Alitretinoin—peripheral nervous system neoplasm	4.41e-05	0.000141	CcSEcCtD
Aripiprazole—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	4.41e-05	0.000141	CcSEcCtD
Aripiprazole—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	4.39e-05	0.000141	CcSEcCtD
Aripiprazole—Bradycardia—Epirubicin—peripheral nervous system neoplasm	4.39e-05	0.00014	CcSEcCtD
Aripiprazole—Headache—Alitretinoin—peripheral nervous system neoplasm	4.38e-05	0.00014	CcSEcCtD
Aripiprazole—Renal failure—Doxorubicin—peripheral nervous system neoplasm	4.37e-05	0.00014	CcSEcCtD
Aripiprazole—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	4.35e-05	0.000139	CcSEcCtD
Aripiprazole—Urticaria—Etoposide—peripheral nervous system neoplasm	4.34e-05	0.000139	CcSEcCtD
Aripiprazole—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	4.33e-05	0.000139	CcSEcCtD
Aripiprazole—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	4.33e-05	0.000139	CcSEcCtD
Aripiprazole—Jaundice—Doxorubicin—peripheral nervous system neoplasm	4.33e-05	0.000139	CcSEcCtD
Aripiprazole—Rhinitis—Epirubicin—peripheral nervous system neoplasm	4.32e-05	0.000138	CcSEcCtD
Aripiprazole—Body temperature increased—Etoposide—peripheral nervous system neoplasm	4.32e-05	0.000138	CcSEcCtD
Aripiprazole—Abdominal pain—Etoposide—peripheral nervous system neoplasm	4.32e-05	0.000138	CcSEcCtD
Aripiprazole—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	4.32e-05	0.000138	CcSEcCtD
Aripiprazole—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	4.32e-05	0.000138	CcSEcCtD
Aripiprazole—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	4.31e-05	0.000138	CcSEcCtD
Aripiprazole—Hepatitis—Epirubicin—peripheral nervous system neoplasm	4.31e-05	0.000138	CcSEcCtD
Aripiprazole—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	4.29e-05	0.000137	CcSEcCtD
Aripiprazole—Vomiting—Vincristine—peripheral nervous system neoplasm	4.29e-05	0.000137	CcSEcCtD
Aripiprazole—Asthenia—Cisplatin—peripheral nervous system neoplasm	4.28e-05	0.000137	CcSEcCtD
Aripiprazole—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	4.28e-05	0.000137	CcSEcCtD
Aripiprazole—Sweating—Doxorubicin—peripheral nervous system neoplasm	4.26e-05	0.000136	CcSEcCtD
Aripiprazole—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	4.26e-05	0.000136	CcSEcCtD
Aripiprazole—Rash—Vincristine—peripheral nervous system neoplasm	4.25e-05	0.000136	CcSEcCtD
Aripiprazole—Dermatitis—Vincristine—peripheral nervous system neoplasm	4.25e-05	0.000136	CcSEcCtD
Aripiprazole—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	4.25e-05	0.000136	CcSEcCtD
Aripiprazole—Haematuria—Doxorubicin—peripheral nervous system neoplasm	4.24e-05	0.000136	CcSEcCtD
Aripiprazole—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	4.24e-05	0.000136	CcSEcCtD
Aripiprazole—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	4.22e-05	0.000135	CcSEcCtD
Aripiprazole—Headache—Vincristine—peripheral nervous system neoplasm	4.22e-05	0.000135	CcSEcCtD
Aripiprazole—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	4.2e-05	0.000134	CcSEcCtD
Aripiprazole—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	4.19e-05	0.000134	CcSEcCtD
Aripiprazole—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	4.17e-05	0.000133	CcSEcCtD
Aripiprazole—Nausea—Alitretinoin—peripheral nervous system neoplasm	4.16e-05	0.000133	CcSEcCtD
Aripiprazole—Visual impairment—Epirubicin—peripheral nervous system neoplasm	4.15e-05	0.000133	CcSEcCtD
Aripiprazole—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	4.15e-05	0.000133	CcSEcCtD
Aripiprazole—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	4.08e-05	0.000131	CcSEcCtD
Aripiprazole—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	4.06e-05	0.00013	CcSEcCtD
Aripiprazole—Eye disorder—Epirubicin—peripheral nervous system neoplasm	4.03e-05	0.000129	CcSEcCtD
Aripiprazole—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	4.02e-05	0.000129	CcSEcCtD
Aripiprazole—Tinnitus—Epirubicin—peripheral nervous system neoplasm	4.02e-05	0.000129	CcSEcCtD
Aripiprazole—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	4.01e-05	0.000128	CcSEcCtD
Aripiprazole—Nausea—Vincristine—peripheral nervous system neoplasm	4.01e-05	0.000128	CcSEcCtD
Aripiprazole—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	4e-05	0.000128	CcSEcCtD
Aripiprazole—Flushing—Epirubicin—peripheral nervous system neoplasm	4e-05	0.000128	CcSEcCtD
Aripiprazole—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	4e-05	0.000128	CcSEcCtD
Aripiprazole—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	3.99e-05	0.000128	CcSEcCtD
Aripiprazole—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	3.99e-05	0.000128	CcSEcCtD
Aripiprazole—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	3.97e-05	0.000127	CcSEcCtD
Aripiprazole—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	3.96e-05	0.000127	CcSEcCtD
Aripiprazole—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	3.94e-05	0.000126	CcSEcCtD
Aripiprazole—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	3.93e-05	0.000126	CcSEcCtD
Aripiprazole—Asthenia—Etoposide—peripheral nervous system neoplasm	3.92e-05	0.000125	CcSEcCtD
Aripiprazole—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	3.92e-05	0.000125	CcSEcCtD
Aripiprazole—Angiopathy—Epirubicin—peripheral nervous system neoplasm	3.91e-05	0.000125	CcSEcCtD
Aripiprazole—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	3.91e-05	0.000125	CcSEcCtD
Aripiprazole—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	3.89e-05	0.000125	CcSEcCtD
Aripiprazole—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	3.88e-05	0.000124	CcSEcCtD
Aripiprazole—Chills—Epirubicin—peripheral nervous system neoplasm	3.87e-05	0.000124	CcSEcCtD
Aripiprazole—Pruritus—Etoposide—peripheral nervous system neoplasm	3.86e-05	0.000124	CcSEcCtD
Aripiprazole—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	3.84e-05	0.000123	CcSEcCtD
Aripiprazole—Alopecia—Epirubicin—peripheral nervous system neoplasm	3.81e-05	0.000122	CcSEcCtD
Aripiprazole—Vomiting—Cisplatin—peripheral nervous system neoplasm	3.79e-05	0.000121	CcSEcCtD
Aripiprazole—Mental disorder—Epirubicin—peripheral nervous system neoplasm	3.78e-05	0.000121	CcSEcCtD
Aripiprazole—Rash—Cisplatin—peripheral nervous system neoplasm	3.76e-05	0.00012	CcSEcCtD
Aripiprazole—Dermatitis—Cisplatin—peripheral nervous system neoplasm	3.76e-05	0.00012	CcSEcCtD
Aripiprazole—Malnutrition—Epirubicin—peripheral nervous system neoplasm	3.75e-05	0.00012	CcSEcCtD
Aripiprazole—Erythema—Epirubicin—peripheral nervous system neoplasm	3.75e-05	0.00012	CcSEcCtD
Aripiprazole—Diarrhoea—Etoposide—peripheral nervous system neoplasm	3.74e-05	0.00012	CcSEcCtD
Aripiprazole—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	3.73e-05	0.000119	CcSEcCtD
Aripiprazole—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	3.72e-05	0.000119	CcSEcCtD
Aripiprazole—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	3.7e-05	0.000118	CcSEcCtD
Aripiprazole—Flushing—Doxorubicin—peripheral nervous system neoplasm	3.7e-05	0.000118	CcSEcCtD
Aripiprazole—Flatulence—Epirubicin—peripheral nervous system neoplasm	3.7e-05	0.000118	CcSEcCtD
Aripiprazole—Tension—Epirubicin—peripheral nervous system neoplasm	3.68e-05	0.000118	CcSEcCtD
Aripiprazole—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	3.67e-05	0.000118	CcSEcCtD
Aripiprazole—Nervousness—Epirubicin—peripheral nervous system neoplasm	3.64e-05	0.000117	CcSEcCtD
Aripiprazole—Back pain—Epirubicin—peripheral nervous system neoplasm	3.63e-05	0.000116	CcSEcCtD
Aripiprazole—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	3.62e-05	0.000116	CcSEcCtD
Aripiprazole—Dizziness—Etoposide—peripheral nervous system neoplasm	3.61e-05	0.000116	CcSEcCtD
Aripiprazole—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	3.61e-05	0.000115	CcSEcCtD
Aripiprazole—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	3.6e-05	0.000115	CcSEcCtD
Aripiprazole—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	3.59e-05	0.000115	CcSEcCtD
Aripiprazole—Chills—Doxorubicin—peripheral nervous system neoplasm	3.58e-05	0.000115	CcSEcCtD
Aripiprazole—Nausea—Cisplatin—peripheral nervous system neoplasm	3.54e-05	0.000113	CcSEcCtD
Aripiprazole—Vision blurred—Epirubicin—peripheral nervous system neoplasm	3.54e-05	0.000113	CcSEcCtD
Aripiprazole—Alopecia—Doxorubicin—peripheral nervous system neoplasm	3.52e-05	0.000113	CcSEcCtD
Aripiprazole—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	3.49e-05	0.000112	CcSEcCtD
Aripiprazole—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	3.48e-05	0.000111	CcSEcCtD
Aripiprazole—Vomiting—Etoposide—peripheral nervous system neoplasm	3.47e-05	0.000111	CcSEcCtD
Aripiprazole—Erythema—Doxorubicin—peripheral nervous system neoplasm	3.47e-05	0.000111	CcSEcCtD
Aripiprazole—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	3.47e-05	0.000111	CcSEcCtD
Aripiprazole—Anaemia—Epirubicin—peripheral nervous system neoplasm	3.47e-05	0.000111	CcSEcCtD
Aripiprazole—Agitation—Epirubicin—peripheral nervous system neoplasm	3.45e-05	0.00011	CcSEcCtD
Aripiprazole—Rash—Etoposide—peripheral nervous system neoplasm	3.44e-05	0.00011	CcSEcCtD
Aripiprazole—Dermatitis—Etoposide—peripheral nervous system neoplasm	3.44e-05	0.00011	CcSEcCtD
Aripiprazole—Headache—Etoposide—peripheral nervous system neoplasm	3.42e-05	0.00011	CcSEcCtD
Aripiprazole—Flatulence—Doxorubicin—peripheral nervous system neoplasm	3.42e-05	0.000109	CcSEcCtD
Aripiprazole—Tension—Doxorubicin—peripheral nervous system neoplasm	3.41e-05	0.000109	CcSEcCtD
Aripiprazole—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	3.4e-05	0.000109	CcSEcCtD
Aripiprazole—Malaise—Epirubicin—peripheral nervous system neoplasm	3.38e-05	0.000108	CcSEcCtD
Aripiprazole—Nervousness—Doxorubicin—peripheral nervous system neoplasm	3.37e-05	0.000108	CcSEcCtD
Aripiprazole—Vertigo—Epirubicin—peripheral nervous system neoplasm	3.37e-05	0.000108	CcSEcCtD
Aripiprazole—Syncope—Epirubicin—peripheral nervous system neoplasm	3.36e-05	0.000108	CcSEcCtD
Aripiprazole—Leukopenia—Epirubicin—peripheral nervous system neoplasm	3.36e-05	0.000107	CcSEcCtD
Aripiprazole—Back pain—Doxorubicin—peripheral nervous system neoplasm	3.36e-05	0.000107	CcSEcCtD
Aripiprazole—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	3.34e-05	0.000107	CcSEcCtD
Aripiprazole—Palpitations—Epirubicin—peripheral nervous system neoplasm	3.32e-05	0.000106	CcSEcCtD
Aripiprazole—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	3.3e-05	0.000106	CcSEcCtD
Aripiprazole—Cough—Epirubicin—peripheral nervous system neoplasm	3.27e-05	0.000105	CcSEcCtD
Aripiprazole—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	3.27e-05	0.000105	CcSEcCtD
Aripiprazole—Convulsion—Epirubicin—peripheral nervous system neoplasm	3.25e-05	0.000104	CcSEcCtD
Aripiprazole—Nausea—Etoposide—peripheral nervous system neoplasm	3.24e-05	0.000104	CcSEcCtD
Aripiprazole—Hypertension—Epirubicin—peripheral nervous system neoplasm	3.24e-05	0.000104	CcSEcCtD
Aripiprazole—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	3.22e-05	0.000103	CcSEcCtD
Aripiprazole—Anaemia—Doxorubicin—peripheral nervous system neoplasm	3.21e-05	0.000103	CcSEcCtD
Aripiprazole—Arthralgia—Epirubicin—peripheral nervous system neoplasm	3.19e-05	0.000102	CcSEcCtD
Aripiprazole—Chest pain—Epirubicin—peripheral nervous system neoplasm	3.19e-05	0.000102	CcSEcCtD
Aripiprazole—Myalgia—Epirubicin—peripheral nervous system neoplasm	3.19e-05	0.000102	CcSEcCtD
Aripiprazole—Agitation—Doxorubicin—peripheral nervous system neoplasm	3.19e-05	0.000102	CcSEcCtD
Aripiprazole—Anxiety—Epirubicin—peripheral nervous system neoplasm	3.18e-05	0.000102	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	3.17e-05	0.000102	CcSEcCtD
Aripiprazole—Discomfort—Epirubicin—peripheral nervous system neoplasm	3.16e-05	0.000101	CcSEcCtD
Aripiprazole—Malaise—Doxorubicin—peripheral nervous system neoplasm	3.13e-05	0.0001	CcSEcCtD
Aripiprazole—Dry mouth—Epirubicin—peripheral nervous system neoplasm	3.12e-05	0.0001	CcSEcCtD
Aripiprazole—Vertigo—Doxorubicin—peripheral nervous system neoplasm	3.12e-05	9.98e-05	CcSEcCtD
Aripiprazole—Syncope—Doxorubicin—peripheral nervous system neoplasm	3.11e-05	9.96e-05	CcSEcCtD
Aripiprazole—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	3.11e-05	9.95e-05	CcSEcCtD
Aripiprazole—Confusional state—Epirubicin—peripheral nervous system neoplasm	3.09e-05	9.88e-05	CcSEcCtD
Aripiprazole—Palpitations—Doxorubicin—peripheral nervous system neoplasm	3.07e-05	9.82e-05	CcSEcCtD
Aripiprazole—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	3.06e-05	9.8e-05	CcSEcCtD
Aripiprazole—Oedema—Epirubicin—peripheral nervous system neoplasm	3.06e-05	9.8e-05	CcSEcCtD
Aripiprazole—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	3.05e-05	9.77e-05	CcSEcCtD
Aripiprazole—Infection—Epirubicin—peripheral nervous system neoplasm	3.04e-05	9.74e-05	CcSEcCtD
Aripiprazole—Cough—Doxorubicin—peripheral nervous system neoplasm	3.03e-05	9.7e-05	CcSEcCtD
Aripiprazole—Shock—Epirubicin—peripheral nervous system neoplasm	3.01e-05	9.64e-05	CcSEcCtD
Aripiprazole—Convulsion—Doxorubicin—peripheral nervous system neoplasm	3.01e-05	9.63e-05	CcSEcCtD
Aripiprazole—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	3e-05	9.61e-05	CcSEcCtD
Aripiprazole—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	3e-05	9.6e-05	CcSEcCtD
Aripiprazole—Hypertension—Doxorubicin—peripheral nervous system neoplasm	3e-05	9.59e-05	CcSEcCtD
Aripiprazole—Tachycardia—Epirubicin—peripheral nervous system neoplasm	2.99e-05	9.57e-05	CcSEcCtD
Aripiprazole—Skin disorder—Epirubicin—peripheral nervous system neoplasm	2.97e-05	9.52e-05	CcSEcCtD
Aripiprazole—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	2.96e-05	9.48e-05	CcSEcCtD
Aripiprazole—Chest pain—Doxorubicin—peripheral nervous system neoplasm	2.96e-05	9.46e-05	CcSEcCtD
Aripiprazole—Myalgia—Doxorubicin—peripheral nervous system neoplasm	2.96e-05	9.46e-05	CcSEcCtD
Aripiprazole—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	2.96e-05	9.46e-05	CcSEcCtD
Aripiprazole—Anxiety—Doxorubicin—peripheral nervous system neoplasm	2.95e-05	9.43e-05	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	2.94e-05	9.4e-05	CcSEcCtD
Aripiprazole—Discomfort—Doxorubicin—peripheral nervous system neoplasm	2.92e-05	9.35e-05	CcSEcCtD
Aripiprazole—Anorexia—Epirubicin—peripheral nervous system neoplasm	2.92e-05	9.34e-05	CcSEcCtD
Aripiprazole—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	2.89e-05	9.25e-05	CcSEcCtD
Aripiprazole—Hypotension—Epirubicin—peripheral nervous system neoplasm	2.86e-05	9.16e-05	CcSEcCtD
Aripiprazole—Confusional state—Doxorubicin—peripheral nervous system neoplasm	2.86e-05	9.14e-05	CcSEcCtD
Aripiprazole—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	2.83e-05	9.07e-05	CcSEcCtD
Aripiprazole—Oedema—Doxorubicin—peripheral nervous system neoplasm	2.83e-05	9.07e-05	CcSEcCtD
Aripiprazole—Infection—Doxorubicin—peripheral nervous system neoplasm	2.81e-05	9.01e-05	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	2.79e-05	8.93e-05	CcSEcCtD
Aripiprazole—Shock—Doxorubicin—peripheral nervous system neoplasm	2.79e-05	8.92e-05	CcSEcCtD
Aripiprazole—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	2.78e-05	8.89e-05	CcSEcCtD
Aripiprazole—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	2.77e-05	8.88e-05	CcSEcCtD
Aripiprazole—Insomnia—Epirubicin—peripheral nervous system neoplasm	2.77e-05	8.86e-05	CcSEcCtD
Aripiprazole—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	2.77e-05	8.85e-05	CcSEcCtD
Aripiprazole—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	2.75e-05	8.81e-05	CcSEcCtD
Aripiprazole—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	2.75e-05	8.8e-05	CcSEcCtD
Aripiprazole—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	2.74e-05	8.77e-05	CcSEcCtD
Aripiprazole—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	2.73e-05	8.74e-05	CcSEcCtD
Aripiprazole—Somnolence—Epirubicin—peripheral nervous system neoplasm	2.72e-05	8.71e-05	CcSEcCtD
Aripiprazole—Anorexia—Doxorubicin—peripheral nervous system neoplasm	2.7e-05	8.64e-05	CcSEcCtD
Aripiprazole—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	2.7e-05	8.63e-05	CcSEcCtD
Aripiprazole—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	2.66e-05	8.52e-05	CcSEcCtD
Aripiprazole—Hypotension—Doxorubicin—peripheral nervous system neoplasm	2.65e-05	8.47e-05	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	2.64e-05	8.46e-05	CcSEcCtD
Aripiprazole—Fatigue—Epirubicin—peripheral nervous system neoplasm	2.64e-05	8.45e-05	CcSEcCtD
Aripiprazole—Pain—Epirubicin—peripheral nervous system neoplasm	2.62e-05	8.38e-05	CcSEcCtD
Aripiprazole—Constipation—Epirubicin—peripheral nervous system neoplasm	2.62e-05	8.38e-05	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	2.58e-05	8.26e-05	CcSEcCtD
Aripiprazole—Insomnia—Doxorubicin—peripheral nervous system neoplasm	2.56e-05	8.2e-05	CcSEcCtD
Aripiprazole—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	2.54e-05	8.14e-05	CcSEcCtD
Aripiprazole—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	2.53e-05	8.09e-05	CcSEcCtD
Aripiprazole—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	2.52e-05	8.08e-05	CcSEcCtD
Aripiprazole—Somnolence—Doxorubicin—peripheral nervous system neoplasm	2.52e-05	8.06e-05	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	2.5e-05	8.01e-05	CcSEcCtD
Aripiprazole—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	2.49e-05	7.98e-05	CcSEcCtD
Aripiprazole—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	2.46e-05	7.88e-05	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	2.45e-05	7.83e-05	CcSEcCtD
Aripiprazole—Fatigue—Doxorubicin—peripheral nervous system neoplasm	2.44e-05	7.82e-05	CcSEcCtD
Aripiprazole—Urticaria—Epirubicin—peripheral nervous system neoplasm	2.43e-05	7.79e-05	CcSEcCtD
Aripiprazole—Pain—Doxorubicin—peripheral nervous system neoplasm	2.42e-05	7.76e-05	CcSEcCtD
Aripiprazole—Constipation—Doxorubicin—peripheral nervous system neoplasm	2.42e-05	7.76e-05	CcSEcCtD
Aripiprazole—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	2.42e-05	7.75e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	2.42e-05	7.75e-05	CcSEcCtD
Aripiprazole—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	2.33e-05	7.47e-05	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	2.32e-05	7.42e-05	CcSEcCtD
Aripiprazole—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	2.26e-05	7.22e-05	CcSEcCtD
Aripiprazole—Urticaria—Doxorubicin—peripheral nervous system neoplasm	2.25e-05	7.2e-05	CcSEcCtD
Aripiprazole—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	2.24e-05	7.17e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	2.24e-05	7.17e-05	CcSEcCtD
Aripiprazole—Asthenia—Epirubicin—peripheral nervous system neoplasm	2.2e-05	7.03e-05	CcSEcCtD
Aripiprazole—Pruritus—Epirubicin—peripheral nervous system neoplasm	2.17e-05	6.93e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	2.09e-05	6.71e-05	CcSEcCtD
Aripiprazole—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	2.09e-05	6.68e-05	CcSEcCtD
Aripiprazole—Asthenia—Doxorubicin—peripheral nervous system neoplasm	2.03e-05	6.51e-05	CcSEcCtD
Aripiprazole—Dizziness—Epirubicin—peripheral nervous system neoplasm	2.02e-05	6.48e-05	CcSEcCtD
Aripiprazole—Pruritus—Doxorubicin—peripheral nervous system neoplasm	2e-05	6.42e-05	CcSEcCtD
Aripiprazole—Vomiting—Epirubicin—peripheral nervous system neoplasm	1.95e-05	6.23e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	1.94e-05	6.2e-05	CcSEcCtD
Aripiprazole—Rash—Epirubicin—peripheral nervous system neoplasm	1.93e-05	6.18e-05	CcSEcCtD
Aripiprazole—Dermatitis—Epirubicin—peripheral nervous system neoplasm	1.93e-05	6.17e-05	CcSEcCtD
Aripiprazole—Headache—Epirubicin—peripheral nervous system neoplasm	1.92e-05	6.14e-05	CcSEcCtD
Aripiprazole—Dizziness—Doxorubicin—peripheral nervous system neoplasm	1.87e-05	6e-05	CcSEcCtD
Aripiprazole—Nausea—Epirubicin—peripheral nervous system neoplasm	1.82e-05	5.82e-05	CcSEcCtD
Aripiprazole—Vomiting—Doxorubicin—peripheral nervous system neoplasm	1.8e-05	5.77e-05	CcSEcCtD
Aripiprazole—Rash—Doxorubicin—peripheral nervous system neoplasm	1.79e-05	5.72e-05	CcSEcCtD
Aripiprazole—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	1.78e-05	5.71e-05	CcSEcCtD
Aripiprazole—Headache—Doxorubicin—peripheral nervous system neoplasm	1.77e-05	5.68e-05	CcSEcCtD
Aripiprazole—Nausea—Doxorubicin—peripheral nervous system neoplasm	1.68e-05	5.39e-05	CcSEcCtD
Aripiprazole—CHRM5—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	6.71e-06	9.01e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.7e-06	8.99e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Hemostasis—AKT1—peripheral nervous system neoplasm	6.65e-06	8.93e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.6e-06	8.86e-05	CbGpPWpGaD
Aripiprazole—HTR2B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	6.6e-06	8.85e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	6.56e-06	8.81e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	6.56e-06	8.8e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	6.55e-06	8.79e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.53e-06	8.77e-05	CbGpPWpGaD
Aripiprazole—CHRM5—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	6.53e-06	8.76e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	6.51e-06	8.74e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	6.51e-06	8.74e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.5e-06	8.72e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.49e-06	8.7e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.48e-06	8.7e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.47e-06	8.68e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.46e-06	8.67e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.44e-06	8.64e-05	CbGpPWpGaD
Aripiprazole—HTR1E—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.43e-06	8.62e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	6.4e-06	8.58e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	6.39e-06	8.57e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.38e-06	8.56e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.38e-06	8.56e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	6.38e-06	8.56e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.37e-06	8.54e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.36e-06	8.53e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.35e-06	8.52e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.33e-06	8.49e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	6.31e-06	8.47e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	6.27e-06	8.42e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.27e-06	8.41e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.25e-06	8.38e-05	CbGpPWpGaD
Aripiprazole—DRD1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	6.22e-06	8.35e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	6.19e-06	8.31e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.16e-06	8.27e-05	CbGpPWpGaD
Aripiprazole—DRD3—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	6.14e-06	8.23e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.1e-06	8.19e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.08e-06	8.16e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.05e-06	8.12e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—NRAS—peripheral nervous system neoplasm	6e-06	8.05e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.99e-06	8.04e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.99e-06	8.04e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.95e-06	7.99e-05	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.95e-06	7.98e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.93e-06	7.95e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	5.91e-06	7.93e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.84e-06	7.83e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.83e-06	7.82e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.81e-06	7.79e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.81e-06	7.79e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.75e-06	7.72e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.74e-06	7.7e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.7e-06	7.65e-05	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.69e-06	7.63e-05	CbGpPWpGaD
Aripiprazole—HTR1E—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.67e-06	7.61e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.66e-06	7.6e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.65e-06	7.58e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.65e-06	7.58e-05	CbGpPWpGaD
Aripiprazole—ADRB1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	5.59e-06	7.5e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.59e-06	7.5e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.58e-06	7.49e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.57e-06	7.48e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.56e-06	7.46e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.55e-06	7.44e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	5.55e-06	7.44e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	5.54e-06	7.43e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.54e-06	7.43e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.5e-06	7.38e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.49e-06	7.37e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.48e-06	7.35e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.47e-06	7.34e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.43e-06	7.29e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.42e-06	7.27e-05	CbGpPWpGaD
Aripiprazole—HTR1A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	5.35e-06	7.18e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.34e-06	7.17e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.32e-06	7.14e-05	CbGpPWpGaD
Aripiprazole—HTR2C—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	5.32e-06	7.14e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.3e-06	7.11e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.29e-06	7.1e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.27e-06	7.07e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.27e-06	7.07e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.24e-06	7.03e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	5.21e-06	7e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	5.18e-06	6.94e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.17e-06	6.93e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.13e-06	6.88e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.13e-06	6.88e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.1e-06	6.85e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.1e-06	6.84e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	5.09e-06	6.83e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.08e-06	6.81e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.05e-06	6.78e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.05e-06	6.77e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.04e-06	6.77e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.03e-06	6.75e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.03e-06	6.75e-05	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.02e-06	6.74e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.02e-06	6.73e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5e-06	6.71e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.95e-06	6.64e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.94e-06	6.63e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.86e-06	6.52e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.83e-06	6.48e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.83e-06	6.48e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.81e-06	6.46e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.75e-06	6.38e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.75e-06	6.37e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.74e-06	6.36e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.73e-06	6.34e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.71e-06	6.32e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.7e-06	6.31e-05	CbGpPWpGaD
Aripiprazole—DRD2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.7e-06	6.3e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.67e-06	6.26e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.65e-06	6.24e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.65e-06	6.24e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.64e-06	6.23e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.63e-06	6.21e-05	CbGpPWpGaD
Aripiprazole—HTR2A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.62e-06	6.2e-05	CbGpPWpGaD
Aripiprazole—HRH1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.61e-06	6.19e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.6e-06	6.17e-05	CbGpPWpGaD
Aripiprazole—CHRM1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.6e-06	6.17e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.59e-06	6.16e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.59e-06	6.16e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.59e-06	6.15e-05	CbGpPWpGaD
Aripiprazole—CHRM3—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.58e-06	6.15e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.58e-06	6.14e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.57e-06	6.13e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.56e-06	6.11e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.55e-06	6.11e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.54e-06	6.09e-05	CbGpPWpGaD
Aripiprazole—CHRM2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.54e-06	6.09e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.52e-06	6.07e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.49e-06	6.03e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.48e-06	6.01e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.46e-06	5.98e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.44e-06	5.96e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.42e-06	5.93e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.39e-06	5.89e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.39e-06	5.89e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.38e-06	5.88e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.36e-06	5.85e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.33e-06	5.81e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.33e-06	5.8e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.32e-06	5.8e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.3e-06	5.77e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.29e-06	5.75e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.27e-06	5.72e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.26e-06	5.72e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	4.26e-06	5.71e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.23e-06	5.68e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.2e-06	5.64e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.2e-06	5.63e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.2e-06	5.63e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.19e-06	5.62e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.19e-06	5.62e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	4.18e-06	5.6e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.17e-06	5.6e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.16e-06	5.59e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.16e-06	5.58e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.15e-06	5.56e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.14e-06	5.56e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.14e-06	5.55e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.12e-06	5.53e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.12e-06	5.52e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.11e-06	5.51e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.01e-06	5.38e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—MYC—peripheral nervous system neoplasm	4e-06	5.37e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.97e-06	5.32e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.95e-06	5.3e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.94e-06	5.29e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.9e-06	5.23e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.9e-06	5.23e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.88e-06	5.2e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.87e-06	5.2e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.85e-06	5.16e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.84e-06	5.15e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.83e-06	5.14e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	3.82e-06	5.12e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.82e-06	5.12e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.8e-06	5.1e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.78e-06	5.07e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.77e-06	5.06e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.77e-06	5.05e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.76e-06	5.04e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.73e-06	5e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.71e-06	4.97e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.66e-06	4.91e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.63e-06	4.87e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.57e-06	4.8e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.57e-06	4.79e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.56e-06	4.77e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.55e-06	4.77e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.54e-06	4.76e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.54e-06	4.75e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.52e-06	4.72e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.51e-06	4.71e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.5e-06	4.7e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.5e-06	4.7e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.49e-06	4.68e-05	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—AKT1—peripheral nervous system neoplasm	3.42e-06	4.59e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.4e-06	4.56e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.4e-06	4.56e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.38e-06	4.54e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.37e-06	4.52e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.34e-06	4.48e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—AKT1—peripheral nervous system neoplasm	3.32e-06	4.46e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.29e-06	4.42e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.29e-06	4.41e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.25e-06	4.36e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.25e-06	4.36e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.24e-06	4.34e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.23e-06	4.34e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.14e-06	4.22e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.09e-06	4.15e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3e-06	4.02e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.98e-06	4e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.97e-06	3.99e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—AKT1—peripheral nervous system neoplasm	2.94e-06	3.94e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.94e-06	3.94e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.93e-06	3.93e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.92e-06	3.92e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.91e-06	3.91e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.88e-06	3.87e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.87e-06	3.86e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.87e-06	3.85e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.85e-06	3.83e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.85e-06	3.83e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.81e-06	3.77e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.8e-06	3.76e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.79e-06	3.75e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.78e-06	3.73e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.78e-06	3.73e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.76e-06	3.7e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.75e-06	3.69e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.73e-06	3.67e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—AKT1—peripheral nervous system neoplasm	2.7e-06	3.62e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.67e-06	3.58e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.55e-06	3.43e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.52e-06	3.38e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.48e-06	3.33e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.47e-06	3.32e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—AKT1—peripheral nervous system neoplasm	2.47e-06	3.32e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.47e-06	3.31e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.46e-06	3.3e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.43e-06	3.27e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.43e-06	3.26e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.26e-06	3.03e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	1.86e-06	2.5e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	1.76e-06	2.36e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	1.15e-06	1.54e-05	CbGpPWpGaD
